PROGRAM DETAILS
You are cordially invited to participate in a patient profile-based program focused on the use of BLENREP for appropriate patients with relapsed/refractory multiple myeloma. This program is organized around a patient profile and is intended to allow for audience interaction through discussion of BLENREP clinical data and guidance for management of patients who are receiving BLENREP. During small group discussions with an expert, you will learn about the multimodal mechanism of BLENREP and the efficacy and safety profile demonstrated in DREAMM-2, the clinical study that supported the accelerated approval of BLENREP.
Presented by
Patricia Mangan, RN, MSN, APRN
Abramson Cancer Center, UPENN
Date and Time
Tuesday, October 25th, 2022
6:30pm EST
Location
Strega Italiano
1 Marina Park Drive
Boston, Massachusetts 02210
RSVP to Amy Crean at amy.s.crean@gsk.com or call 1-781-706-5983
CODE 221025-BLE-81471
Comments